Today, the Federal Trade Commission (FTC) sent warning letters to 10 drug manufacturers challenging the “junk listings” of more than 300 patents in the FDA Orange Book for medicines treating diabetes, weight loss, asthma, and COPD. These letters follow FTC challenges to improper Orange Book patent listings last November, which were followed by companies delisting several of the challenged patents. Public Citizen’s Access to Medicines program advocate, Steve Knievel, issued the following statement... Читать дальше...